CClinicalTrials.gg
CompletedNCT04889248Updated May 27, 2022

Inspiratory Muscle Training With Powerbreath Device in Patients With ALS

An interventional study of Inspiratory Muscle Training with Powerbreath IMT device. in Amyotrophic Lateral Sclerosis, sponsored by Universidad Francisco de Vitoria. Completed at 1 site in Spain. Per ClinicalTrials.gov, last updated 2022-05-27.

Sponsored by Universidad Francisco de Vitoria · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Sex
All
01

Study summary

Abstract:

Context/background: people affected by Amyotrophic Lateral Sclerosis (ALS) see their own life totally disturbed after the diagnosis. This disease also courses, apart from the functional and depressing worsening, with internal damage manifested by a cardio respiratory deterioration. There are not many clinical studies publications about this disease given that is considered a weird illness with short prognosis.

Objectives: to examine the effects of the inspiratory muscle training (IMT) on respiratory muscle strength, heart rate variability (HRV), quality of life and mood in patients with ALS.

Methods: 20 volunteer patients, male and female, with ALS, bulbar or spinal will take part of the cuasi-experimental study and they will be divided into two groups: an experimental group (n = 10) and a control group (n = 10). The Maximum Inspiratory Pressure (PIM), the HRV, the quality of life and mood will be measured. The participants of experimental group will conduct 30 inspirations per day, 15 in the morning and 15 in the evening, 5 days per week, through 8 weeks. The resistance of the training in the experimental group will be increase acording to the PIM measured at the first visit. During the first week, the resistance will be at 30% of PImax, weeks 2 and 3 at 40%, weeks 4 and 5 at 50% and the last 3 weeks at 60%. After 8 weeks, all participants will fill up again all scales and post training measurements will be taken.

02

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic lateral sclerosis
  • Maximum Inspiratory Pressure
  • Diaphragm
03

In context

Respiratory Aspiration

1,092 studies on the registry are indexed under Respiratory Aspiration; 216 are open to participants now.

This study's enrollment of 20 is below the median of 42 across 881 interventional studies indexed under Respiratory Aspiration.

Browse Respiratory Aspiration studies →

Lead sponsor

Universidad Francisco de Vitoria is the lead sponsor of 52 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Subjects with ALS

Exclusion criteria

Exclusion Criteria:

  • PImax more than 30mmH2O
  • Score higher than 2 in GDS Reisberg scale
  • Using already respiratory devices during the day (except night CPAPs support) more than 14h/day.
  • Unstable medical disease for the last 3 years.
  • Use of IMT contraindicated for medical reasons.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Intervention

    Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Treatment as usual

    Other: Inspiratory Muscle Training with Powerbreath IMT device.

  • No intervention
    Control

    Without inspiratory muscle training. Treatment as usual.

Interventions

  • OtherInspiratory Muscle Training with Powerbreath IMT device.

    Inspiratory muscle training with Powerbreath IMT device, for a duration of 8 weeks. Each day, each subject perform 15 repetitions in the morning and evening, from Monday to Friday, resting on weekends. The endurance of the device increases along the study, initiating with the 30% of their own maximum inspiratory pressure (PImax) during the first week and increasing a 10% every other week, till reach the goal of 60% PImax.

06

What researchers measure

Primary outcomes

  1. PImax

    Maximum Inspiratory Pressure

    Time frame: 8 weeks

Secondary outcomes

  1. HRV

    Heart Rate Variability

    Time frame: 8 weeks

  2. HR

    Heart Rate

    Time frame: 8 weeks

  3. ALSAQ-40

    The Amyotrophic Lateral Sclerosis Assessment Questionnaire

    Time frame: 8 weeks

  4. ALSFRS-R

    ALS Functional Rating Scale Revised

    Time frame: 8 weeks

  5. Beck scale

    Depression scale

    Time frame: 8 weeks

07

Study locations

1 site
  • Universidad Francisco de Vitoria
    Pozuelo De Alarcón, Madrid 28223, Spain
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04889248
Lead sponsor
Universidad Francisco de Vitoria
Responsible party
Sponsor
First posted
May 17, 2021
Start date
May 17, 2021
Primary completion
Sep 12, 2021
Completion
Nov 12, 2021
Last update
May 27, 2022

Study contacts

Davinia Vicente Campos, PhD
principal investigator · Universidad Francisco de Vitoria

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion